Welcome to our dedicated page for Metagenomi news (Ticker: MGX), a resource for investors and traders seeking the latest updates and insights on Metagenomi stock.
Metagenomi, Inc. (Nasdaq: MGX) is a leading precision genetic medicines company dedicated to developing curative therapeutics for patients through its advanced, metagenomics-derived genome editing toolbox. The company's innovative platform includes programmable nucleases, base editors, and both RNA and DNA-mediated integration systems such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi's mission is to address the diverse mutations causing genetic diseases, which have largely been unapproachable by previous genome engineering methods.
In 2023, Metagenomi achieved significant milestones, such as demonstrating preclinical proof of concept in nonhuman primates for its lead Hemophilia A program. This included the successful integration of a functional Factor VIII gene, resulting in clinically relevant Factor VIII levels over a 4.5-month follow-up period. The company is on track to nominate a Development Candidate for this program by mid-2024 and aims to present 12-month durability data later in the year.
Key partnerships have also advanced, with Ionis Pharmaceuticals completing target selection for multiple collaboration efforts, focusing on diseases like Transthyretin Amyloidosis and Cardiovascular Disease. Metagenomi's technology platform continues to make groundbreaking advancements, particularly with its Big RIGS (RNA-mediated integration systems) and CAST systems, highlighting the company's capacity to perform large, targeted gene integrations.
The company's proprietary SMART base editors, some of the smallest in the industry, underline its leadership in genome editing. These editors have been engineered to be highly efficient and are suitable for a broad range of therapeutic applications.
In early 2024, Metagenomi announced the successful closing of its initial public offering, raising approximately $93.75 million. This funding will support the company’s continued research and development efforts, including advancing two INDs and nominating two additional Development Candidates. Metagenomi's strong financial position, with $271.2 million in cash and marketable securities as of December 31, 2023, plus the IPO proceeds, ensures a robust cash runway to support its ambitious goals.
Corporate infrastructure has been bolstered with key executive appointments, including Sarah Noonberg as Chief Medical Officer, Luis Borges as Chief Scientific Officer, and Pamela Wapnick as Chief Financial Officer. These strategic hires are pivotal in driving the company's clinical development and operational expansion.
Metagenomi recently regained full control over its base editing and RIGS technologies, previously under collaboration with Moderna, allowing the company to further its mission in developing gene editing therapies for conditions with significant unmet needs like Alpha-1 Antitrypsin Deficiency and Wilson’s Disease.
For more information, please visit Metagenomi's official website.
Metagenomi (Nasdaq: MGX) has provided updates on its therapeutic development programs and outlined key milestones for 2025-2026. The company reported significant progress in its MGX-001 hemophilia A program, achieving sustained Factor VIII activity in nonhuman primate studies over 16+ months. The company plans regulatory interactions in 2025 and IND/CTA submissions in 2026.
The company is advancing its secreted protein deficiencies program, expecting NHP proof-of-concept in 2025 and development candidate nomination in 2026. In collaboration with Ionis, Metagenomi is progressing on cardiometabolic programs, targeting one to two development candidate nominations in 2025.
Metagenomi has also advanced its technology platforms, including compact SMART nucleases and novel Adenine Base Editors. The company's cash runway is expected to support operations into 2027.
Metagenomi (Nasdaq: MGX) has announced the appointment of Eric Bjerkholt, MBA, to its Board of Directors, effective January 27, 2025. Bjerkholt, currently CFO of Mirum Pharmaceuticals, will serve on Metagenomi's Audit and Compensation committees.
Bjerkholt brings significant pharmaceutical industry experience, having served as CFO at several companies including Chinook Therapeutics (acquired by Novartis AG) and Aimmune Therapeutics (acquired by Nestle Health Science). At Sunesis Pharmaceuticals, he held multiple executive roles including Executive VP of Corporate Development and Finance. His background includes healthcare investment banking at J.P. Morgan and senior finance roles at various companies.
Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO and founder, Brian C. Thomas, PhD, will deliver a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PT in San Francisco.
The presentation will be accessible through a live webcast on the investor section of Metagenomi's website at https://ir.metagenomi.co/. A replay option will be available for a time at the same web address. Metagenomi specializes in developing curative therapeutics using its proprietary gene editing toolbox.
Metagenomi (Nasdaq: MGX) presented data demonstrating the precision and safety of its gene editing tools at the Nature Conference: RNA at the Bench and Bedside IV. The company highlighted two key developments: MGX-001, their hemophilia A candidate using the MG29-1 nuclease, showed no identifiable off-target editing and no evidence of translocations in primary human hepatocytes. Additionally, their Adenine Base Editor (ABE) for ex vivo cell therapy demonstrated no detectable translocations and no significant genomic base composition differences in primary T-cells compared to unedited cells.
Metagenomi (MGX) presented updated preclinical data for its hemophilia A program at the ASH 66th Annual Meeting. The company's gene editing approach demonstrated sustained Factor VIII (FVIII) activity levels through more than 16 months in nonhuman primates (NHPs). The study involved three NHPs receiving a single treatment, showing FVIII activity maintenance at 72%, 9%, and 30% at the 16.5-month timepoint.
The company's lead candidate, MGX-001, which uses a B-domain deleted bioengineered FVIII construct, achieved higher FVIII activity compared to wild type FVIII at similar integration rates. The program is on track for IND filing in 2026. The treatment showed only transient elevation of liver transaminases with no other safety concerns, positioning it as a potential one-time curative treatment for both adults and children with hemophilia A.
Metagenomi (MGX) reported Q3 2024 financial results and business updates, highlighting the nomination of MGX-001, their first development candidate for hemophilia A treatment. The company demonstrated successful proof-of-concept with durable Factor VIII activity levels over 12 months in nonhuman primates. Financial highlights include $274.6 million in cash and equivalents, with runway into 2027. R&D expenses were $26.3 million and G&A expenses were $7.6 million. The company expects one to two development candidate nominations in 2025 from their Ionis collaboration programs focusing on cardiometabolic indications.
Metagenomi (Nasdaq: MGX) announced that its abstract on Factor VIII gene insertion has been accepted for oral presentation at the American Society of Hematology (ASH) 66th Annual Meeting in December 2024. The presentation will showcase preclinical proof-of-concept data for their lead candidate MGX-001, which aims to provide a single, curative treatment for hemophilia A.
The research demonstrates durable Factor VIII expression in nonhuman primates, addressing current therapy limitations that fail to prevent breakthrough bleeding. The presentation, led by VP Preclinical Alan Brooks, PhD, is scheduled for December 9, 2024, at 5:30 PM in San Diego Convention Center.
Metagenomi presented groundbreaking results for its Adenine Base Editors (ABEs) at the European Society of Gene and Cell Therapy Annual Congress in Rome. The company's ABE platform demonstrated exceptional performance across key metrics: over 95% genome targetability, achieving 95% protein knockdown in primary T-cells through triplex editing, and highly specific on-target deamination with no detectable translocations.
The platform showed excellent tolerability with no adverse effects on cell viability or expansion. Notable advantages include compatibility with various non-viral methods of site-specific template integration, enabling an all-in-one editing solution for next-generation cell therapies. This positions Metagenomi's ABE technology as a promising tool for both in vivo genome editing programs and ex vivo cell therapy applications.
Metagenomi (Nasdaq: MGX) presented a poster at the AIChE 7th International Conference on CRISPR Technologies, highlighting their SMART adenine base editors (ABEs). These compact editors are small enough to be packaged into a single adeno-associated virus (AAV), potentially addressing a key challenge in in vivo gene editing.
The company's SMART platform demonstrates improved editing efficiency across multiple targets and cell types, enabling pursuit of neuromuscular targets. This approach could be advantageous for treating diseases like Duchenne muscular dystrophy, ALS, and Charcot-Marie-Tooth disease type 1A.
Metagenomi has optimized the SMART platform through structure-guided engineering and advanced artificial intelligence (AI) tools, showcasing the importance of leveraging multiple techniques to advance next-generation gene editing systems.
Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference on September 30, 2024. The company will be involved in two key events:
1. A fireside chat from 2:30 PM to 3:00 PM ET, featuring CEO and Founder Brian Thomas, CMO Dr. Sarah Noonberg, and SVP Preclinical Alan Brooks.
2. A panel discussion titled "Genome editing for gene insertion and gene correction - where we are and what's next" from 5:00 PM to 5:30 PM ET, with CEO Brian C. Thomas participating.
A live webcast of the fireside chat will be available on the company's investor relations website, with replays of both events accessible for a time.
FAQ
What is the current stock price of Metagenomi (MGX)?
What is the market cap of Metagenomi (MGX)?
What is the primary focus of Metagenomi, Inc.?
What are some key achievements of Metagenomi in 2023?
What recent partnerships has Metagenomi engaged in?
What is the significance of Metagenomi's initial public offering?
What financial position did Metagenomi report at the end of 2023?
Who are some key members of Metagenomi's leadership team?
What technologies is Metagenomi developing?
What are Metagenomi's plans for its Hemophilia A program?
What is the significance of regaining full rights to base editing and RIGS technologies?
Where can I find more information about Metagenomi?
